Beyond TIGIT: Lessons from a failed immune checkpoint for rational target discovery.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitors have shown limited clinical success.
• Understanding the mechanisms of TIGIT action and its relationship with PD-1 (programmed cell death protein 1) is crucial for improving cancer immunotherapy.
• Lack of predictive biomarkers has hindered patient selection for TIGIT-targeted therapies.

Purpose of the Study:

• To analyze the reasons behind the clinical failure of TIGIT inhibitors.
• To propose strategies for future development of TIGIT-based cancer immunotherapies.
• To highlight the importance of rigorous scientific investigation over accelerated commercialization.

Main Methods:

• Review of existing clinical trial data for TIGIT inhibitors.
• Analysis of preclinical research on TIGIT and PD-1 pathways.
• Comparative assessment of TIGIT and PD-1 functions in cancer immunology.

Main Results:

• Clinical failures were attributed to incomplete mechanistic insights, absence of predictive biomarkers, and functional overlap with PD-1.
• TIGIT inhibitors may be less effective in unselected patient populations or when PD-1 is already targeted.
• Significant redundancy exists between TIGIT and PD-1 pathways in regulating T cell responses.

Conclusions:

• Future TIGIT inhibitor development should prioritize PD-1-refractory tumors.
• Enhanced humanized models are needed to better predict clinical efficacy.
• Co-development of diagnostics and therapeutics is essential for advancing TIGIT-based immunotherapy.
• A focus on fundamental science is critical for overcoming current limitations and achieving clinical success.